Evidence map›Paper›PMID 39729317›Full record

ArticleJAMA network open2024

Estimated Vaccine Effectiveness for Pediatric Patients With Severe Influenza, 2015-2020.

Kelsey M Sumner, Leila C Sahni, Julie A Boom, Natasha B Halasa, Laura S Stewart, Janet A Englund, Eileen J Klein, Mary A Staat, Elizabeth P Schlaudecker, Rangaraj Selvarangan and 12 more

Abstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Kelsey M SumnerInfluenza Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia.
Leila C SahniDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas.
Julie A BoomDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas.
Natasha B HalasaVanderbilt University Medical Center, Nashville, Tennessee.
Laura S StewartVanderbilt University Medical Center, Nashville, Tennessee.
Janet A EnglundSeattle Children's Research Institute, Seattle, Washington.
Eileen J KleinSeattle Children's Research Institute, Seattle, Washington.
Mary A StaatCincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Elizabeth P SchlaudeckerCincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Rangaraj SelvaranganUniversity of Missouri-Kansas City School of Medicine, Children's Mercy Kansas City, Kansas City.
Christopher J HarrisonUniversity of Missouri-Kansas City School of Medicine, Children's Mercy Kansas City, Kansas City.
Geoffrey A WeinbergUniversity of Rochester School of Medicine and Dentistry, Rochester, New York.
Peter G SzilagyiUniversity of Rochester School of Medicine and Dentistry, Rochester, New York.
Monica N SingerUniversity of California, San Francisco Benioff Children's Hospital Oakland, Oakland.
Parvin H AzimiUniversity of California, San Francisco Benioff Children's Hospital Oakland, Oakland.
Benjamin R ClopperCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia.
Heidi L MolineCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia.
Emma K NobleInfluenza Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia.
John V WilliamsUPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Marian G MichaelsUPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Samantha M OlsonInfluenza Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia.
New Vaccine Surveillance Network Collaborators

Funding

NCIRD CDC HHS U01 IP001049NCIRD CDC HHS U01 IP001054NCIRD CDC HHS U01 IP001152NCIRD CDC HHS U01 IP001156NCIRD CDC HHS U01 IP001157NCIRD CDC HHS U01 IP001158
6 · The paper itself

Abstract

Importance: Increasing the understanding of vaccine effectiveness (VE) against levels of severe influenza in children could help increase uptake of influenza vaccination and strengthen vaccine policies globally. Objective: To investigate VE in children by severity of influenza illness. Design, Setting, and Participants: This case-control study with a test-negative design used data from 8 participating medical centers located in geographically different US states in the New Vaccine Surveillance Network from November 6, 2015, through April 8, 2020. Participants included children 6 months through 17 years of age who were hospitalized or presented to an emergency department (ED) with acute respiratory illness. Exposures: Receipt of at least 1 dose of the current season's influenza vaccine. Main Outcomes and Measures: Demographic and clinical characteristics of patients presenting to the hospital or ED with or without influenza were recorded and grouped by influenza vaccination status. Estimated VE against severe influenza illness was calculated using multiple measures to capture illness severity. Data were analyzed between June 1, 2022, and September 30, 2023. Results: Among 15 728 children presenting for care with acute respiratory illness (8708 [55.4%] male; 13 450 [85.5%] 6 months to 8 years of age and 2278 [14.5%] 9-17 years of age), 2710 (17.2%) had positive influenza tests and 13 018 (82.8%) had negative influenza tests (controls). Of the influenza test-positive cases, 1676 children (61.8%) had an ED visit, 896 children (33.1%) required hospitalization for noncritical influenza, and 138 children (5.1%) required hospitalization for critical influenza. About half (7779 [49.5%]) of the children (both influenza test positive and test negative) were vaccinated. Receiving at least 1 influenza vaccine dose was estimated to have a VE of 55.7% (95% CI, 51.6%-59.6%) for preventing influenza-associated ED visits or hospitalizations among children of all ages. The estimated VE was similar across severity levels: 52.8% (95% CI, 46.6%-58.3%) for ED visits, 52.3% (95% CI, 44.8%-58.8%) for noncritical hospitalization, and 50.4% (95% CI, 29.7%-65.3%) for critical hospitalization. Conclusions and Relevance: Findings from this case-control study with a test-negative design involving children with a spectrum of influenza severity suggest that influenza vaccination protects children against all levels of severe influenza illness.

Indexed as

Influenza, HumanInfluenza VaccinesVaccine EfficacyAdolescentCase-Control StudiesChildChild, PreschoolEmergency Service, HospitalFemaleHospitalizationHumansInfantMaleSeverity of Illness IndexUnited StatesVaccinationInfluenza Vaccines

Identifiers

PMID39729317
PMCPMC11681373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.